← All trials
NCT06248671
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Feb 28, 2029
- First posted
- Feb 8, 2024
- Last posted
- Jul 3, 2024
- Enrollment
- 450
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- Oslo Metropolitan UniversityOfficial
- University Hospital of North NorwayCollaborator
- Oslo Metropolitan UniversityCollaborator
- Norwegian University of Science and TechnologyOfficial
- University of BergenOfficial
- University of OsloCollaborator
- University of OsloCollaborator
- University of Northern NorwayOfficial
- University of BergenCollaborator
- University of OsloOfficial
- University of OsloOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.